| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Investigations |
1 Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
2 Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
3 Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
PET studies have been performed using the amyloid binding radiotracer Pittsburgh Compound B (PIB). Previous quantitative analyses using arterial blood showed that the Logan graphical analysis using 90 min of emission data (ART90) provided a reliable measure of PIB retention. This work reports on simplified methods of analysis for human PIB imaging. Methods: PIB PET scans were conducted in 24 subjects (6 Alzheimer’s disease [AD], 10 mild cognitive impairment [MCI], 8 controls) with arterial blood sampling. Retest scans were performed on 8 subjects (3 AD, 1 MCI, 4 controls) within 28 d. Data were analyzed over 60 and 90 min using the Logan analysis and (a) metabolite-corrected input functions based on arterial plasma (ART60, ART90), (b) carotid artery time–activity data with a population average metabolite correction (CAR60, CAR90); and (c) cerebellar reference tissue (CER60, CER90). Data also were analyzed using the simplified reference tissue method (SRTM60, SRTM90) and a single-scan method based on late-scan ratios of standardized uptake values (SUVR60, SUVR90). Results: All methods of analysis examined effectively discerned regional differences between AD and control subjects in amyloid-laden cortical regions, although the performance of the simplified methods varied in terms of bias, test–retest variability, intersubject variability, and effect size. CAR90 best agreed with ART90 distribution volume ratio (DVR) measures across brain regions and subject groups and demonstrated satisfactory test–retest variability (±7.1% across regions). CER90 and CER60 showed negative biases relative to ART90 in high-DVR subjects but had the lowest test–retest variability. The single-scan SUV-based methods showed the largest effect sizes for AD and control group differences and performed well in terms of intersubject and test–retest variability. Conclusion: Of the simplified methods for PIB analysis examined, CAR90 provided DVR measures that were most comparable to ART90; CER90 was the most reproducible and SUVR90 produced the largest effect size. All simplified methods were effective at distinguishing AD and control differences and may be effectively used in the analysis of PIB. SUVR60 data can be obtained with as little as 20 min of PET emission data collection. The relative strengths and limitations of each method must be considered for each experimental design.
Key Words: PET • Alzheimer’s disease • amyloid • Pittsburgh Compound B
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  V. J. Lowe, B. J. Kemp, C. R. Jack Jr., M. Senjem, S. Weigand, M. Shiung, G. Smith, D. Knopman, B. Boeve, B. Mullan, et al. Comparison of 18F-FDG and PiB PET in Cognitive Impairment J. Nucl. Med., June 1, 2009; 50(6): 878 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Jack Jr, V. J. Lowe, S. D. Weigand, H. J. Wiste, M. L. Senjem, D. S. Knopman, M. M. Shiung, J. L. Gunter, B. F. Boeve, B. J. Kemp, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease Brain, May 1, 2009; 132(5): 1355 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Frisoni, M. Lorenzi, A. Caroli, N. Kemppainen, K. Nagren, and J. O. Rinne In vivo mapping of amyloid toxicity in Alzheimer disease Neurology, April 28, 2009; 72(17): 1504 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu, W. Lee, N. Ayutyanont, J. Keppler, S. A. Reeder, J. B. S. Langbaum, et al. Fibrillar amyloid-{beta} burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease PNAS, April 21, 2009; 106(16): 6820 - 6825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. McNamee, S.-H. Yee, J. C. Price, W. E. Klunk, B. Rosario, L. Weissfeld, S. Ziolko, M. Berginc, B. Lopresti, S. DeKosky, et al. Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements J. Nucl. Med., March 1, 2009; 50(3): 348 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Buckner, J. Sepulcre, T. Talukdar, F. M. Krienen, H. Liu, T. Hedden, J. R. Andrews-Hanna, R. A. Sperling, and K. A. Johnson Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease J. Neurosci., February 11, 2009; 29(6): 1860 - 1873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Tolboom, M. Yaqub, W. M. van der Flier, R. Boellaard, G. Luurtsema, A. D. Windhorst, F. Barkhof, P. Scheltens, A. A. Lammertsma, and B. N.M. van Berckel Detection of Alzheimer Pathology In Vivo Using Both 11C-PIB and 18F-FDDNP PET J. Nucl. Med., February 1, 2009; 50(2): 191 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Okello, P. Edison, H. A. Archer, F. E. Turkheimer, J. Kennedy, R. Bullock, Z. Walker, A. Kennedy, N. Fox, M. Rossor, et al. Microglial activation and amyloid deposition in mild cognitive impairment: A PET study Neurology, January 6, 2009; 72(1): 56 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Wiley, B. J. Lopresti, S. Venneti, J. Price, W. E. Klunk, S. T. DeKosky, and C. A. Mathis Carbon 11-Labeled Pittsburgh Compound B and Carbon 11-Labeled (R)-PK11195 Positron Emission Tomographic Imaging in Alzheimer Disease Arch Neurol, January 1, 2009; 66(1): 60 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Edison, C C Rowe, J O Rinne, S Ng, I Ahmed, N Kemppainen, V L Villemagne, G O'Keefe, K Nagren, K R Chaudhury, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography J. Neurol. Neurosurg. Psychiatry, December 1, 2008; 79(12): 1331 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Aizenstein, R. D. Nebes, J. A. Saxton, J. C. Price, C. A. Mathis, N. D. Tsopelas, S. K. Ziolko, J. A. James, B. E. Snitz, P. R. Houck, et al. Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly Arch Neurol, November 1, 2008; 65(11): 1509 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Klunk Biopsy Support for the Validity of Pittsburgh Compound B Positron Emission Tomography With a Twist Arch Neurol, October 1, 2008; 65(10): 1281 - 1283. [Full Text] [PDF]
|
|
|
|
|
|
S. N. Gomperts, D. M. Rentz, E. Moran, J. A. Becker, J. J. Locascio, W. E. Klunk, C. A. Mathis, D. R. Elmaleh, T. Shoup, A. J. Fischman, et al. Imaging amyloid deposition in Lewy body diseases Neurology, September 16, 2008; 71(12): 903 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mikhno, D. Devanand, G. Pelton, K. Cuasay, R. Gunn, N. Upton, R. Y. Lai, V. Libri, J. J. Mann, and R. V. Parsey Voxel-Based Analysis of 11C-PIB Scans for Diagnosing Alzheimer's Disease J. Nucl. Med., August 1, 2008; 49(8): 1262 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ikonomovic, W. E. Klunk, E. E. Abrahamson, C. A. Mathis, J. C. Price, N. D. Tsopelas, B. J. Lopresti, S. Ziolko, W. Bi, W. R. Paljug, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain, June 1, 2008; 131(6): 1630 - 1645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bolmont, F. Haiss, D. Eicke, R. Radde, C. A. Mathis, W. E. Klunk, S. Kohsaka, M. Jucker, and M. E. Calhoun Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque Maintenance J. Neurosci., April 16, 2008; 28(16): 4283 - 4292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Jack Jr, V. J. Lowe, M. L. Senjem, S. D. Weigand, B. J. Kemp, M. M. Shiung, D. S. Knopman, B. F. Boeve, W. E. Klunk, C. A. Mathis, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment Brain, March 1, 2008; 131(3): 665 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nelissen, M. Vandenbulcke, K. Fannes, A. Verbruggen, R. Peeters, P. Dupont, K. Van Laere, G. Bormans, and R. Vandenberghe A{beta} amyloid deposition in the language system and how the brain responds Brain, August 1, 2007; 130(8): 2055 - 2069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Klunk, J. C. Price, C. A. Mathis, N. D. Tsopelas, B. J. Lopresti, S. K. Ziolko, W. Bi, J. A. Hoge, A. D. Cohen, M. D. Ikonomovic, et al. Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees J. Neurosci., June 6, 2007; 27(23): 6174 - 6184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Rowe, S. Ng, U. Ackermann, S. J. Gong, K. Pike, G. Savage, T. F. Cowie, K. L. Dickinson, P. Maruff, D. Darby, et al. Imaging {beta}-amyloid burden in aging and dementia Neurology, May 15, 2007; 68(20): 1718 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Rabinovici, A. J. Furst, J. P. O'Neil, C. A. Racine, E. C. Mormino, S. L. Baker, S. Chetty, P. Patel, T. A. Pagliaro, W. E. Klunk, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration Neurology, April 10, 2007; 68(15): 1205 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ng, V. L. Villemagne, S. Berlangieri, S.-T. Lee, M. Cherk, S. J. Gong, U. Ackermann, T. Saunder, H. Tochon-Danguy, G. Jones, et al. Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease J. Nucl. Med., April 1, 2007; 48(4): 547 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kudo, N. Okamura, S. Furumoto, M. Tashiro, K. Furukawa, M. Maruyama, M. Itoh, R. Iwata, K. Yanai, and H. Arai 2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients J. Nucl. Med., April 1, 2007; 48(4): 553 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Edison, H. A. Archer, R. Hinz, A. Hammers, N. Pavese, Y. F. Tai, G. Hotton, D. Cutler, N. Fox, A. Kennedy, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study Neurology, February 13, 2007; 68(7): 501 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Kemppainen, S. Aalto, I. A. Wilson, K. Nagren, S. Helin, A. Bruck, V. Oikonen, M. Kailajarvi, M. Scheinin, M. Viitanen, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease Neurology, November 14, 2006; 67(9): 1575 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Klunk, C. A. Mathis, J. C. Price, B. J. Lopresti, and S. T. DeKosky Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain, November 1, 2006; 129(Pt 11): 2805 - 2807. [Full Text] [PDF]
|
|
|
|
|
|
H. Engler, A. Forsberg, O. Almkvist, G. Blomquist, E. Larsson, I. Savitcheva, A. Wall, A. Ringheim, B. Langstrom, and A. Nordberg Two-year follow-up of amyloid deposition in patients with Alzheimer's disease Brain, November 1, 2006; 129(11): 2856 - 2866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Terry Alzheimer's Disease and the Aging Brain J Geriatr Psychiatry Neurol, September 1, 2006; 19(3): 125 - 128. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Mintun, G. N. LaRossa, Y. I. Sheline, C. S. Dence, S. Y. Lee, R. H. Mach, W. E. Klunk, C. A. Mathis, S. T. DeKosky, and J. C. Morris [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease Neurology, August 8, 2006; 67(3): 446 - 452. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
